Catalyst Capital Advisors LLC lowered its holdings in shares of Amarin Co. plc (NASDAQ:AMRN) by 4.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 233,000 shares of the biopharmaceutical company’s stock after selling 12,000 shares during the period. Catalyst Capital Advisors LLC owned about 0.07% of Amarin worth $4,518,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Deutsche Bank AG grew its position in shares of Amarin by 11,077.9% in the 4th quarter. Deutsche Bank AG now owns 183,877 shares of the biopharmaceutical company’s stock valued at $2,502,000 after purchasing an additional 182,232 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Amarin during the 1st quarter worth approximately $196,000. Dupont Capital Management Corp acquired a new position in Amarin during the 1st quarter worth approximately $738,000. Janney Montgomery Scott LLC boosted its position in Amarin by 41.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 30,200 shares of the biopharmaceutical company’s stock worth $627,000 after acquiring an additional 8,900 shares during the last quarter. Finally, Tocqueville Asset Management L.P. boosted its position in Amarin by 721.1% during the 1st quarter. Tocqueville Asset Management L.P. now owns 125,225 shares of the biopharmaceutical company’s stock worth $2,600,000 after acquiring an additional 109,975 shares during the last quarter. Hedge funds and other institutional investors own 47.94% of the company’s stock.
Shares of NASDAQ:AMRN traded down $0.02 during midday trading on Friday, reaching $16.73. 127,495 shares of the company traded hands, compared to its average volume of 6,576,359. The company has a quick ratio of 1.76, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. Amarin Co. plc has a 12 month low of $2.65 and a 12 month high of $23.91. The firm has a market capitalization of $5.83 billion, a price-to-earnings ratio of -42.91 and a beta of 1.27. The firm’s fifty day moving average price is $16.08 and its two-hundred day moving average price is $18.42.
Amarin (NASDAQ:AMRN) last posted its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Amarin had a negative return on equity of 111.75% and a negative net margin of 27.51%. The business had revenue of $100.40 million during the quarter, compared to analysts’ expectations of $99.54 million. During the same period in the previous year, the business earned ($0.10) earnings per share. The firm’s revenue was up 90.9% on a year-over-year basis. Analysts forecast that Amarin Co. plc will post -0.2 earnings per share for the current year.
A number of equities analysts have weighed in on AMRN shares. HC Wainwright reaffirmed a “buy” rating on shares of Amarin in a research report on Thursday, August 1st. Zacks Investment Research lowered Amarin from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Jefferies Financial Group set a $30.00 price objective on Amarin and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Roth Capital set a $31.00 target price on Amarin and gave the stock a “buy” rating in a report on Friday, September 6th. Finally, Cantor Fitzgerald set a $35.00 price objective on Amarin and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Amarin currently has an average rating of “Buy” and an average price target of $29.50.
In other Amarin news, CFO Michael Wayne Kalb sold 50,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $19.67, for a total transaction of $983,500.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Joseph S. Zakrzewski sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $19.02, for a total value of $1,902,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 659,202 shares of company stock valued at $13,058,754 over the last 90 days. 2.75% of the stock is currently owned by company insiders.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.